Clinical Trial Detail

NCT ID NCT02117297
Title SCT Plus Immune Therapy in Average Risk AML/MDS
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York Medical College
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin

Age Groups: adult child

No variant requirements are available.